Fortress Biotech

FBIO · NASDAQ

$1.94+$0.07 (+3.74%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.87

FBIO analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $5.10 (+162.9% upside)

Low: $5.05
Now: $1.94
High: $5.25

Upgrades and downgrades

The latest rating actions, newest first

FBIO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Feb 23, 2026	Maintains	Buy	$17.00	40%

The case for and against

Updated May 8, 2025

Bull case

Fortress Biotech Inc. is poised for significant financial growth, with projected revenue in its Dermatology segment, particularly through the anticipated success of Emrosi, expected to double the revenue base by 2025 and potentially quadruple it by 2028. The company's strategic acquisition of Checkpoint Therapeutics positions it to generate positive cash flow, particularly as regulatory approval milestones are met for cosibelimab, enhancing its commercialization prospects. Additionally, Fortress's equity dividend from Urica further strengthens its financial stability, contributing to a robust outlook for the firm.

Bear case

Fortress Biotech Inc faces significant risks impacting its stock outlook, primarily due to heightened competition that could adversely affect market share and revenue generation. The company’s reliance on successful clinical trials, particularly for DFD-29 aimed at treating rosacea, introduces clinical and forecasting uncertainties that may not align with investor expectations, potentially leading to negative financial repercussions. Furthermore, the need for additional financial resources to support its business model further exacerbates its financial risk, particularly if trial outcomes and revenue forecasts fail to meet projected benchmarks.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.